Notably, rearrangements involving the gene lysine methyltransferase 2a (KMT2A) at 11q23 rank among the most frequent chromosomal abnormalities in AML, often leading to treatment resistance and relapse (Bill et al., 2020; Issa et al., 2021). This evidence concerns the gene KMT2A and acute myeloid leukemia.